{"doi":"10.1093/ofid/ofu052.383","title":"675Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program","abstract":null,"journal":"Open Forum Infectious Diseases","year":2014,"id":621841,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1606022,"name":"Mark Wilcox","orcid":null,"position":1,"is_corresponding":false},{"id":1606025,"name":"Helen Boucher","orcid":null,"position":2,"is_corresponding":false},{"id":1606026,"name":"George Talbot","orcid":null,"position":3,"is_corresponding":false},{"id":1276082,"name":"Michael Dunne","orcid":null,"position":4,"is_corresponding":false},{"id":1606021,"name":"Sailaja Puttagunta","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"675Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program","abstract":"Background. Dalbavancin is a lipoglycopeptide antibiotic with activity against Gram-positive pathogens and a long half-life allowing for weekly dosing. DISCOVER 1 and 2 were identically designed clinical trials of dalbavancin vs vancomycin (VAN) with option to switch to oral linezolid for the treatment of ABSSSI. We evaluated outcomes of ABSSSI in patients treated with VAN by dosing regimen utilized and serum trough concentrations for VAN. Methods. Both trials were double-blind, double dummy, pharmacist-unblinded randomized trials in which patients with ABSSSI were randomized to receive dalbavancin 1g IV on Day 1 and 500 mg IV on Day 8 or VAN 1g (or 15mg/kg) IV every 12 hours (q12h) for at least 3 days with an option to switch to oral linezolid 600 mg q12h to complete 10-14 days of therapy. The primary endpoint was measured at 48-72 hours of therapy with success requiring cessation of spread of the infection and absence of fever. Secondary endpoints included clinical status at the end of therapy. Outcomes by fixed vs weight-based dosing regimens of VAN and outcomes by serum VAN trough concentrations were analyzed. Results. Please see Tables 1 and 2. Efficacy by fixed* vs weight-based dosing regimen of vancomycin *1 gram intravenously twice daily Conclusion. Clinical response rates for patients with ABSSSI were similar in patients treated with a fixed-dose regimen or weight-based dosing regimen of vancomycin. No association was observed between serum vancomycin trough concentrations and efficacy outcomes at the 48-72 hour time point or at EOT. Disclosures. S. Puttagunta, Durata Therapeutics: Employee and Shareholder, Salary M. Wilcox, Durata Therapeutics: Scientific Advisor, Consulting fee G. Talbot, Durata Therapeutics: Consultant, Scientific Advisor and Shareholder, Consulting fee M. Dunne, Durata Therapeutics: Employee and Shareholder, Salary Efficacy by serum trough vancomycin concentrations","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19767382","pmcid":"PMC5781904","openalex_id":"https://openalex.org/W2201418735","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.13947791,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":null,"oa_locations":[{"url":"https://doi.org/10.1093/ofid/ofu052.383","host_type":"journal"},{"url":"https://doi.org/10.1093/ofid/ofu052.383","host_type":"publisher"},{"url":"http://academic.oup.com/ofid/article-pdf/1/suppl_1/S190/6917737/ofu052.383.pdf","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5781904","host_type":"repository"}],"fields_of_study":["Antimicrobial Resistance in Staphylococcus","Bacterial Identification and Susceptibility Testing","Antifungal resistance and susceptibility"],"mesh_terms":[],"keywords":["Dalbavancin","Dosing","Vancomycin","Medicine","Linezolid","Regimen","Trough Concentration","Antibiotics","Pharmacology","Internal medicine","Staphylococcus aureus","Microbiology","Biology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T16:20:31.626814Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}